Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'


AstraZeneca kicks off second blood cancer launch, this time for orphan drug Lumoxiti.....           Senator to Pfizer CEO: Stop playing 'political games' with drug prices.....           Pfizer still unable to get on top of problems at Hospira injectables plant.....           U.K. cost watchdog NICE issues preliminary ?no? on Alnylam?s Onpattro and Ionis? Tegsedi.....           Johnson & Johnson?s Tremfya tops Novartis blockbuster Cosentyx in head-to-head psoriasis showdown.....           FDA Commissioner Scott Gottlieb blasts insulin pricing, unveils move to bolster biosimilar competition.....           As competition heats up, U.S. prices for Remicade and biosims slip: analyst.....           China's Zhejiang Huahai lambasted in FDA warning letter for putting profits ahead of safety.....           China's Zhejiang Huahai lambasted in FDA warning letter for putting profits ahead of safety.....           Boehringer Ingelheim chops 295 jobs in France but vows $380M in animal health investments.....           Boehringer Ingelheim chops 295 jobs in France but vows $380M in animal health investments.....           Merck promotes oncology, vaccine executives to replace Adam Schechter in commercial rejig.....           Merck promotes oncology, vaccine executives to replace Adam Schechter in commercial rejig.....           GlaxoSmithKline's Shingrix shortage expected to persist 'throughout 2019'.....           GlaxoSmithKline's Shingrix shortage expected to persist 'throughout 2019'.....           Cannes Lions Health preps for 6th year, names jury heads for health & wellness, pharma awards.....           Gilead, looking for cancer sales, swipes Roche pharma chief Daniel O'Day for CEO post.....           Akorn's CEO bows out after failing last-ditch bid to save Fresenius merger.....           Generics 'cartel' probe expands to a whopping 300 drugs: report.....           Gilead, looking for cancer sales, swipes Roche pharma chief O'Day for CEO post.....           Acadia debuts first Nuplazid branded ads, aiming to spark talk of Parkinson's psychosis.....           AbbVie's latest hep C push highlights Mavyret's time-to-cure advantage.....           AbbVie's Humira still leads pharma?s TV ad spending, but new ads for Aimovig, Mavyret and Truvada pop in November.....           Ra Pharma?s zilucoplan meets primary endpoints in phase 2 gMG trial.....           Janssen?s Tremfya meets primary endpoint in phase 3 psoriasis trial.....           Weizmann researchers discover new neural mechanism underlying anxiety.....           X-Chem, Almirall forge dermatology-focused drug discovery alliance.....           X marks the spot: Merz rolls new Xeomin brand push, awareness effort targeting 'Xennials'.....           Roche?s Tecentriq wins key lung cancer approval. Its prize? A showdown with formidable Merck.....           FiercePharmaAsia?Takeda-Shire finish line; Sun?s crisis; J&J-Legend CAR-T.....           With Tesaro off the block, will Clovis be the next PARP maker to get swallowed up?.....           With pricing outcry raging, U.S. drug spending grew less than 1% last year: CMS.....           Tris Pharma recalls potentially harmful infants' ibuprofen.....           AstraZeneca's Imfinzi fails another phase 3 trial, this time in head and neck cancer.....           Roche?s Tecentriq wins key lung cancer approval. Its prize? A showdown with formidable Merck.....           Actelion inks $360M deal to resolve DOJ kickbacks probe.....           Sanofi plots 670 layoffs in France as local tensions brew.....           Catalent is expanding and adding 36 jobs at its Indiana biologics plant.....           Novartis, aiming to protect blockbuster sales, advances Xolair follow-up to phase 3.....           Akorn fights to salvage Fresenius deal in appeal to Delaware Supreme Court.....           Big pharma?s off-patent drugs lose out in China?s new price-cutting scheme.....           Troubled Mallinckrodt spins off specialty generics business in ongoing effort to reshape its image.....           Sandoz prepares early 2019 launch for EpiPen alternative Symjepi at 16% discount.....           Actelion inks $360M deal to resolve DOJ kickbacks probe.....           Circassia to acquire full US rights of AstraZeneca?s COPD treatment Tudorza.....           Versant Ventures launches new biotech firm Black Diamond Therapeutics.....           Schrödinger, TB Alliance collaborate to advance tuberculosis drug discovery.....           BMS, Vedanta Biosciences to evaluate Opdivo-VE800 combo in metastatic cancers.....           PCI expands cold chain storage capabilities at UK site.....           e-therapeutics, Novo Nordisk enter into research collaboration deal.....           Alnylam, Silence Therapeutics settle patent dispute.....           Klick Health holiday video debuts with fake launch of all-holiday agency 'Klickmas'.....           Roche's Tecentriq lines up for billion-dollar market with FDA priority tag.....           Sanofi merges biology and tech with research deal for digital asthma lab.....           Mismanagement allegations send Sun Pharma stock tumbling: What we know so far.....           Chinese drugmaker pours $145M into plant with plan to produce innovative biologics.....           Taking aim at Medicaid misclassifications like Mylan's EpiPen, senators look to end a 'pharma ripoff'.....           AstraZeneca's Calquence found success in lymphoma. Will CLL follow?.....           Novo keeps adding capacity, and jobs, to its North Carolina drug plant  .....           AstraZeneca?s Imfinzi fails to improve OS in head and neck cancer trial.....           Eisai, UCL to launch phase I trials of E2814 for Alzheimer?s disease.....           French pharma firm Cristers selects Adents Prodigi cloud serialization solution.....           As Amazon takes page from pharma's EHR playbook, smarter DTC could be on the way.....           Janssen, Merck chip in for $100M U.K. vaccine center to help fight epidemics.....           Walmart and Aurobindo sued as litigation mounts over contaminated blood pressure drugs.....           ASH: Johnson & Johnson's fast-growing Darzalex lines up for 2nd front-line myeloma OK.....           ASH: Johnson & Johnson, AbbVie's Imbruvica steals the CLL spotlight with phase 3 study wins.....           Ocular Therapeutix crosses finish line with eye treatment after running down production problems.....           Solicitor general to back Merck at Supreme Court in Fosamax pre-emption case.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
 
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
 
 
Latest news

Kingston University and Athlone Institute of Technology achieve APS accreditation

               

The Academy of Pharmaceutical Sciences (APS) is delighted to announce that two more institutions, Kingston University and Athlone Institute of Technology have recently achieved accreditation having gone through the accreditation process set up by the Academy towards the end of 2017.

APS is delighted that institutions see the value of our accreditation process and several others are in the process of application to us.

Achieving accreditation gives assurance to students and employers that the course meets the high standards required by the Academy and that these standards will be maintained throughout the 5-year period of accreditation.

APS believes that the accreditation process will raise the profile of pharmaceutical sciences in both academia and industry. The discipline is key in the discovery, development and manufacture of new medicines and as such is central to government initiatives to encourage the pharmaceutical industry to maintain and strengthen its strong base in the UK and Ireland.

The APS will continue to work with other stakeholders to build the science base for the ultimate benefit of patients.

To read more on the accreditation process - click here.

 
 
APS events overview

The APS is developing an exciting and informative programme of events in 2019.

Please take a look at our programme here.

OTHER EVENTS IN DEVELOPMENT
Developability for Biologicals
Inhaled Workshop
Basic Biopharmaceutics workshop 

Follow us
 
Upcoming Events
APS Additive Manufacturing Symposium
27 March 2019
APS Developability Workshop
17 - 18 April 2019
APS Industrial Insights 2019
25 - 26 April 2019
10th APS International PharmSci conference 2019
11 - 13 September 2019
Job Vacancies
View all Vacancies
Advertise your job vacancies
The APS is grateful for the support of:
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.

 

Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351, Fax: 0116 274 7365, Email: info@apsgb.org

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.

Privacy Policy:
For details on the data we collect and how we store and process your data please refer to our Privacy Policy.